Dosage regimen for ranitidin in renal impairment. (2). Multiple oral dose studies.
スポンサーリンク
概要
- 論文の詳細を見る
In this study, the dosage regimen for rantidine in patients with renal dysfunction, which was previouly proposed, has been evaluated in patients with renal impairment.<BR>1. Twenty patients with renal impairment with the creatinine clearance (Clcr) of less than 70 ml/min were chosen. The oral dose of ranitidine 50 mg b. i. d. was repeatedly given to five non-dialyzed patients with severe renal impairment with the Clcr of less than 30 ml/min for 14 days, and also ranitidine, 100 mg b. i. d., to five non-dialyzed patients with moderate renal impairment with the Clcr of 30 to 70 ml/min for the same period. The oral dose of ranitidine of 50 mg b. i. d. was repeatedly given for 4 to 5 weeks to ten hemodialyzed patients with renal failure.<BR>2. In the non-dialyzed patients, actual measurement values of plasma ranitidine concentrations after 7 and 14 days of medication were almost in keeping with simulation curve of plasma concentrations at the repeatedly administered period, which were calculated from the results obtained when initially administered. In addition, it was assumed that the maximum steady state plasma concentrations (Css, max) were 409.3±122. 5 ng/ml (patients with severe renal impairment), and 558.0±62.4ng/ml (patients with moderate renal impairment), and the minimum concentrations in steady state (Css, max) were 101.9±26.0ng/ml (patients with severe renal impairment) and 103.3±254ng/ml (patients with moderate renal impairment).<BR>3. Ranitidine was effectively removed from blood by hemodialysis, and Css, max and Css, min in the hemodialyzed patients were considered approximately 320ng/ml and 180ng/ml, respectively.<BR>As stated above, an excess rise of plasma ranitidine concentrations in both non-dialyzed and dialyzed patients was not observed and the sufficient concentrations for proper clinical effects were obtained. Thus, the appropriate ranitidine regimen was proposed for each: 50 mg b. i. d. for the patients with Clcr less than 30 ml/min and 100 mg b. i. d. for the patients with Clcr of 30 to 70 ml/min.
著者
関連論文
- 腹膜透析療法における自己管理・手技・定期検査のあり方
- 血清カルシウム値と頸動脈プラークの関連 : 健診データに基づいた検討
- 大腸がん検診での腫瘍・非腫瘍の鑑別診断における拡大内視鏡の有用性
- フリーテストステロンとED(年齢階級別検討)
- テストステロンと男性更年期症状との関連
- 0260 アンジオテンシン変換酵素遺伝子多型は虚血性心疾患の危険因子か?
- 当院の透析患者の四肢・体幹の特発性出血に関する検討
- 冠動脈バイパス術(CABG)施行後に血液透析(HD)導入された患者の長期予後
- 血液透析導入患者におけるバスキュラーアクセスの選択 : 背景因子の検討
- 留置型血液透析カテーテル先端右房内の巨大血栓を開心術で除去した2例
- 血液透析導入患者の虚血性心臓合併症に関する検討
- 膜性腎症の予後に関する臨床的検討
- 透析患者の虚血性心疾患の臨床的検討
- 血液透析患者における冠状動脈バイパス手術の長期成績
- 維持血液透析中に顕性C型肝炎が急性発症した1例 : HCV-RNAの塩基配列同定による感染源の特定
- メシル酸ナファモスタットによる重篤な薬剤アレルギーの検討
- 慢性透析患者におけるomeprazoleの薬物動態
- 急速進行性糸球体腎炎の発症が先行したP-ANCA高値の慢性関節リウマチの1透析例
- 健常成人におけるバルプロ酸反復投与時の体内動態
- 生活習慣病と酸化ストレス : 人間ドックにおける活性酸素消去酵素活性測定の意義 : (1)肥満
- 企業における健康管理のための健康度評価システム
- 肥満とインスリン抵抗性の指標としての血中レプチン濃度
- 糖尿病患者における高Superoxide dismutase(SOD)血症 : Extracellular(EC)-SOD依存性について
- V.その他のマーカー 糖化アルブミン排泄量でみた微量アルブミンと糖尿病性腎症の進行について
- Electron Spin Resonance (Spin Trapping法)による糖尿病患者血清中のスーパーオキサイド消去活性である総SOD活性,Cu,Zn-SOD活性の測定
- 急性腎不全で発症した両側腎原発悪性リンパ腫の1例
- アスペルギルス性膿胸と二次性副甲状腺機能亢進症を合併した維持透析例
- 禁煙外来受診者の喫煙成功および不成功に関わる因子の検討
- E-PTFEグラフトを用いたブラッドアクセスの長期成績
- 人間ドックにおける寄生虫陽性率の経年的変化
- 14)薬剤不応性心不全患者に対する captopril (SQ14,225)の使用経験 : 日本循環器学会第97回関東甲信越地方会
- 血液透析患者におけるHCVコア蛋白質測定の意義について
- T_2強調画像にて皮質下に高信号を示す病変が認知機能に及ぼす影響について
- 脳MRIによる血液透析患者の無症候性脳虚血病変に関する検討
- 透析患者の冠動脈造影とインターベンション治療:基礎疾患に関する検討
- ヒスタミンH_2受容体遮断薬
- 内視鏡検査による大腸癌検診の有用性とポリープの取り扱い
- 透析と臨床検査(6) : 血液浄化療法とこれからの腎不全治療
- 透析と臨床検査(5) : 透析と臨床検査(2)
- 透析と臨床検査(4) : 透析と臨床検査(1)
- 透析と臨床検査(1) : 透析療法の発展と現状
- 透析中における循環動態についてご教示下さい
- 血管壁エイコサノイド産生能からみた胃大網動脈の冠動脈グラフトとしての適性-第2報
- 人間ドックにおける脂肪肝症例の血清 superoxide dismutase 活性の検討
- 1,5-AG,HbA_,FBG 組合せによる耐糖能障害スクリーニングの検討
- 前立腺ドックにおける freePSA/totalPSA 比の有用性
- 人間ドックにおける寄生虫疾患の現況
- 人間ドックにおける上部消化管検診の有用性と問題点
- 人間ドック受診者のCEA値に及ぼす喫煙の影響
- 高血圧治療の動向
- 透析療法と虚血性心疾患
- 汎下垂体前葉機能低下をきたしたempty sella症候群の1例
- 一卵性双生児の双方に発生した全身性エリテマトーデスの症例
- 低カリウム血症を呈した急性単球性白血病の1例
- Flavobacterium meningosepticumによる亜急性細菌性心内膜炎1例
- 高度の後索変性とbrown bowel症候群を呈しビタミンE欠乏の関与が疑われる1剖検例
- 脳動脈瘤を合併したfibromuscular dysplasiaによる腎血管性高血圧症 : 同胞内に出現した2症例
- Dosage regimen for ranitidin in renal impairment. (2). Multiple oral dose studies.
- A compartment model for a sustained release preparation with zero-order release.
- Assessment of a simple method for acetylator phenotyping with caffeine.
- Polymorphous mode of caffeine metabolism in the Japanese poeple. On genotypes.
- Pharmacokinetics, pharmacodynamics, and safety of bevantolol, a new .BETA.1-selective .BETA.-adrenoceptor antagonist, in Japanese healthy volunteers.
- Clinical pharmacological studies on a new .BETA.1 selective .BETA.-blocker, bevantolol.
- Population pharmacokinetics of theophylline in patients with infantile bronchial asthma.
- Clinical pharmacology of ibopamine. (1). Safety and pharmacological actions after single and multiple oral doses in Japanese healthy subjects.
- Pharmacokinetics of beta-methyldigoxin.
- Clinical pharmacology of nitrendipine - Single- and multiple-dose study in Japanese healthy subjects.:Single- and Multiple-Dose Study in Japanese Healthy Subjects
- Pharmacokinetics of ketoprofen sustained-releasing preparation (RPY-001) in Japanese normal adult persons.
- Pharmacodynamic and pharmacological effects of nipradilol (K-351) in healthy volunteers. Comparison with propranolol.:Comparison with Propranolol
- Influence of beta-adrenergic blocking agent on the circadian rhythm of blood pressure in patients with essential hypertension.
- A case of chronic renal failure with diffuse hepatic and myocardial calcification.
- タイトル無し
- Pharmacokinetics of digoxin in patients with duchenne muscular dystrophy.
- Dosage regimen for ranitidine in renal impairment.
- Effect of premedication term and premedication dose of diltiazem on pharmacokinetics of nifedipine.
- Effect of diltiazem on pharmacokinetics of theophylline.
- Pharmacodynamics and pharmacological actions of MPC-1304, a Ca antagonist, in healthy adults.
- Effects of angiotensin II converting enzyme inhibitor enarapril on autonomic nervous system.
- Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects. Results of multiple oral administration.:Results of Multiple Oral Administration
- Effects of MPC-1304 on blood flow of the finger tip.
- Pharmacokinetics and pharmacodynamic effects of sustained release formulation of urapidil (BKU) in healthy subjects. Results of repeated oral administration.:Results of Repeated Oral Administration
- タイトル無し
- Effect of beta-blockers on circadian rhythm of blood pressure in patients with essential hypertension.
- リウマチ熱心筋炎による心不全と考えられた維持透析患者の1剖検例
- Clinical pharmacology of ibopamine. (2). Pharmacokinetics after single and multiple oral administration in healthy Japanese subjects.
- Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects. Results of single oral administration.:Results of Single Oral Administration
- Pharmacokinetirs of diltiazem in patients with paroxysmal supraventricular tachycardia.
- Various types of caffeine metabolism in Japanese people. Studies by urine per 2 hours.
- Diuretic and uricosuric effects of traxanox sodium in healthy subjects: Comparison with hydrochlorothiazide by multiple-dose study.
- Pharmacokinetic and pharmacological effects of urapidil in healthy volunteers. Comparative study with prazosin.:Comparative Study with Prazosin
- Chronopharmacological study of furosemide in human subjects.
- Pharmacokinetics of beta-methyldigoxin.
- タイトル無し
- タイトル無し
- Pharmacokinetic and pharmacological properties of doxazosin mesilate in Japanese healthy adult volunteers.
- Comparison between direct assay and separating assay of blood beta-methyldigoxin by fluorescent polarized immunoassay.
- タイトル無し
- タイトル無し
- タイトル無し
- Hyperuricemia in solid tumors